Please login to the form below

Not currently logged in
Email:
Password:

Pervasis renal disease drug fast-tracked

Pervasis Therapeutics has been granted fast-track status by the US Food and Drug Administration for Vascugel, a potential new drug for renal disease

Pervasis Therapeutics has been granted fast-track status by the US Food and Drug Administration (FDA) for Vascugel, a potential new drug for the prevention of haemodialysis access failure in patients with end stage renal disease.

The drug, which is the company's lead product, is intended to regulate the body's healing response after surgical interventions to create vascular access points for hemodialysis. Without such treatment, the access points often have difficulty healing and become unusable, leading to multiple complications and additional surgeries, according to the company.

Vascugel, a novel endothelial cell-based therapy, has demonstrated clinical proof of concept in two phase II trials.  The studies, which enrolled patients with end stage renal disease who require a permanent arteriovenous access for haemodialysis, showed that Vascugel offered an improved duration of unimpeded blood flow and a delay in time to first intervention compared to placebo.

The FDA's fast-track programme is designed to speed the development and review of new drugs and vaccines that treat or prevent serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. Under the programme, companies can submit portions of the marketing application to the FDA for review as they are completed.

In addition, the sponsor company of a fast-tracked drug or vaccine is eligible for more frequent meetings and written correspondence with the FDA, and the product candidate is generally eligible for an accelerated approval, which is an approval based on surrogate endpoints.

Vascugel received orphan drug status from the FDA in 2009. The orphan designation, which is intended to encourage development of drugs for conditions that affect fewer than 200,000 Americans, carries potential benefits including tax breaks, research funding, and seven years of US marketing exclusivity.

9th February 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics